Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INSM Stock Forecast 2026-2027
$108.32
Current Price
$23.29B
Market Cap
Buy 22
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INSM Price Targets
+124.3%
To High Target of $243.00
+84.6%
To Median Target of $200.00
+29.2%
To Low Target of $140.00
INSM Price Momentum
-6.3%
1 Week Change
+13.1%
1 Month Change
+5.6%
1 Year Change
-37.8%
Year-to-Date Change
-49.1%
From 52W High of $212.75
+19.8%
From 52W Low of $90.39
📊 TOP ANALYST CALLS
Did INSM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Insmed is one of their latest high-conviction picks.
Latest INSM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, INSM has a bullish consensus with a median price target of $200.00 (ranging from $140.00 to $243.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $108.32, the median forecast implies a 84.6% upside. This outlook is supported by 22 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INSM Analyst Ratings
22
Buy
0
Hold
0
Sell
INSM Price Target Range
Low
$140.00
Average
$200.00
High
$243.00
Current: $108.32
Latest INSM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INSM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 15, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $161.00 |
| Jul 10, 2026 | Guggenheim | Vamil Divan | Buy | Reiterates | $207.00 |
| Jun 22, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Jun 8, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Jun 5, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 14, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 8, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 8, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 8, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Apr 17, 2026 | Roth Capital | Buy | Reiterates | $N/A | |
| Apr 14, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Apr 1, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 30, 2026 | Morgan Stanley | Overweight | Upgrade | $N/A | |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 25, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Mar 24, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Mar 24, 2026 | Stifel | Buy | Maintains | $N/A | |
| Mar 24, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 24, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Mar 23, 2026 | Wells Fargo | Overweight | Maintains | $N/A |
Insmed Inc. (INSM) Competitors
The following stocks are similar to Insmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Insmed Inc. (INSM) Financial Data
Insmed Inc. has a market capitalization of $23.29B with a P/E ratio of -16.7x. The company generates $819.56M in trailing twelve-month revenue with a -144.4% profit margin.
Revenue growth is +229.6% quarter-over-quarter, while maintaining an operating margin of -65.5% and return on equity of -294.5%.
Valuation Metrics
Market Cap
$23.29B
Enterprise Value
$23.32B
P/E Ratio
-16.7x
PEG Ratio
0.4x
Price/Sales
28.4x
Growth & Margins
Revenue Growth (YoY)
+229.6%
Gross Margin
+84.5%
Operating Margin
-65.5%
Net Margin
-144.4%
EPS Growth
+229.6%
Financial Health
Cash/Price Ratio
+5.2%
Current Ratio
4.5x
Debt/Equity
105.3x
ROE
-294.5%
ROA
-31.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Insmed Inc. (INSM) Business Model
About Insmed Inc.
What They Do
Develops therapies for serious and rare diseases.
Business Model
Insmed Inc. operates as a biopharmaceutical company, generating revenue primarily through the commercialization of its products, Arikayce and Brinsupri, which treat respiratory disorders. The company also profits from its diversified clinical pipeline by advancing various drug candidates through development stages, ultimately aiming for regulatory approval and market introduction.
Additional Information
Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed focuses on high-need patient populations, leveraging advanced technologies in research and development. Its commitment to innovation includes exploring gene therapy and AI-driven solutions, positioning the company to address complex health challenges in the United States and other global markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,664
CEO
Mr. William H. Lewis J.D., M.B.A.
Country
United States
IPO Year
2000
Website
www.insmed.comInsmed Inc. (INSM) Latest News & Analysis
Latest News
Quick Summary
Carillon Eagle Mid Cap Growth Fund reported strong second-quarter performance, with top stocks including Datadog, Marvell, Vertiv, Teradyne, and Macom Technology Solutions.
Why It Matters
Strong performance from Carillon Eagle Mid Cap Growth Fund indicates robust growth potential in mid-cap stocks, particularly in tech. This could signal favorable investment opportunities.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
EMBARC plans to collaborate with Insmed on a long-term study to assess Brensocatib's potential in modifying bronchiectasis, enrolling about 3,000 patients in Europe.
Why It Matters
The collaboration between EMBARC and Insmed for a significant study on Brensocatib in bronchiectasis could enhance market potential and investor confidence in both companies' future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Positive
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
25 days ago
Quick Summary
Insmed Incorporated appointed Samuele Butera as Senior VP and General Manager of Global Respiratory, effective June 23, 2026.
Why It Matters
The appointment of Samuele Butera as SVP may signal strategic leadership changes at Insmed, potentially impacting product development and market positioning in the respiratory sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Insmed is rated "Strong Buy" amid strong pipeline progress. Key catalysts include ARIKAYCE's sNDA submission in H2 2026 and ongoing regulatory efforts in Japan, alongside TPIP's phase 3 studies.
Why It Matters
Insmed's strong buy rating reflects confidence in its promising drug pipeline and successful market execution, signaling potential growth and profitability for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
The Nasdaq 100 has completed its June quarterly rebalance, affecting the Invesco QQQ Trust (QQQ) and Invesco Nasdaq 100 ETF (QQQM).
Why It Matters
The Nasdaq 100's quarterly rebalance affects the composition of major ETFs like QQQ and QQQM, influencing their performance and investor strategies.
Source: ETF Trends
Market Sentiment:
Neutral
Quick Summary
Insmed Incorporated (INSM) recently presented at the Goldman Sachs 47th Annual Global Healthcare Conference, showcasing updates and insights relevant to investors.
Why It Matters
Insmed's presentation at a major healthcare conference highlights its strategic direction and potential growth, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About INSM Stock
What is Insmed Inc.'s (INSM) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Insmed Inc. (INSM) has a median price target of $200.00. The highest price target is $243.00 and the lowest is $140.00.
Is INSM stock a good investment in 2027?
According to current analyst ratings, INSM has 22 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $108.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INSM stock?
Wall Street analysts predict INSM stock could reach $200.00 in the next 12 months. This represents a 84.6% increase from the current price of $108.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Insmed Inc.'s business model?
Insmed Inc. operates as a biopharmaceutical company, generating revenue primarily through the commercialization of its products, Arikayce and Brinsupri, which treat respiratory disorders. The company also profits from its diversified clinical pipeline by advancing various drug candidates through development stages, ultimately aiming for regulatory approval and market introduction.
What is the highest forecasted price for INSM Insmed Inc.?
The highest price target for INSM is $243.00 from at , which represents a 124.3% increase from the current price of $108.32.
What is the lowest forecasted price for INSM Insmed Inc.?
The lowest price target for INSM is $140.00 from at , which represents a 29.2% increase from the current price of $108.32.
What is the overall INSM consensus from analysts for Insmed Inc.?
The overall analyst consensus for INSM is bullish. Out of 5 Wall Street analysts, 22 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $200.00.
How accurate are INSM stock price projections?
Stock price projections, including those for Insmed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:34 AM UTC